Genomics Startups

BillionToOne builds a DNA molecular counting technology that increases the resolution of cell-free DNA diagnostics, applied to prenatal screening and liquid biopsy for cancer. Its products serve clinical genetic testing in prenatal care and oncology.

22 investors

HelixNano develops an mRNA platform aimed at applications including cancer treatment, COVID-19 vaccines, and environmental interventions. The company is working on a COVID-19 vaccine candidate for immunocompromised patients and other mRNA-based technologies.

16 investors

Genomelink develops a platform that provides individuals with access to and management of their genomic data, leveraging advances in DNA sequencing technology. The company serves consumers seeking personal genetic information and operates in the genomics and digital health sector.

13 investors

Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models. The company aims to address the global shortage of liver transplants by developing new treatment options for liver fibrosis and cirrhosis.

13 investors

Probably Genetic operates a data platform that finds undiagnosed patients with severe, complex genetic diseases online and analyzes their condition using machine learning and at-home testing. The platform is used by drug developers and patient advocacy groups to help patients access diagnoses, clinical trials, and treatments earlier.

11 investors

54gene is an African genomics company offering research, services, and development focused on including under-represented African genomic data in medical research. It aims to support medical breakthroughs and new healthcare solutions, with a focus on Africans and the global population.

10 investors

Kernal Bio is a synthetic biology company developing selective mRNA drugs to treat serious illnesses, with a focus on cancer therapeutics and improving patient outcomes.

10 investors

Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

10 investors

Nest Genomics develops genomics solutions to integrate genetic testing into routine patient care. The company is led by former Clear Genetics founders and employs genetic counselors and engineers.

8 investors

Arpeggio Bio is a pharmaceutical company that uses AI and high-throughput RNA-sequencing to develop drugs targeting transcription factors, including historically "undruggable" proteins such as NRF2, TEAD, and GPX4. Its lead program targets IO-resistant melanoma, and it has worked on rare disease and inflammation programs through partnerships.

6 investors

Sequence Bio works on drug target discovery, using the Newfoundland founder effect to identify genetic signals of disease and improve the success rate of drug development.

6 investors

Volta develops a hardware and software platform for genomics sample preparation that automates the extraction of biological information. The company serves researchers, laboratories, and healthcare organizations working in genomics, disease control, forensic science, and medicine.

6 investors

CCG.ai develops software for data-driven precision oncology, using clinical and genomic data to identify biomarkers of treatment response and help oncologists choose cancer therapies. It serves clinicians and oncologists in the cancer treatment field.

5 investors

One Codex operates a data platform for applied microbial genomics and metagenomics, supporting applications in clinical diagnostics, food safety, and biosecurity. The company was acquired by Invitae in 2021 and spun out as independent in 2022.

4 investors

Anto is an AI research lab developing foundation models for microbial communities to enable precision medicine by computationally modeling how the microbiome affects individual drug response. The company serves pharmaceutical and clinical research by combining AI with genomic and microbiome data.

3 investors

Coral Genomics develops clinical laboratory tests that combine molecular, functional, and clinical data to predict the most effective treatments for patients with autoimmune diseases. The company also works on addressing a subpopulation of patients who do not respond to current autoimmune therapies.

3 investors

Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.

3 investors

Mable is a genomics-based telehealth platform that provides personalized migraine care by analyzing patients' genetic and biomarker data to inform individualized treatment plans. The company serves migraine sufferers seeking precision medicine alternatives to traditional trial-and-error medication approaches.

3 investors

Sigma Genetics is a biotechnology company developing devices that use magnetic fields to deliver DNA, RNA, and other charged molecules into cells as an alternative to conventional electroporation. The platform technology targets applications including cell therapies, cancer drug delivery, DNA vaccines, biopharma manufacturing, and cosmetics.

3 investors

WhiteLab Genomics uses AI and computational methods to analyze biological data and accelerate genomic drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to reduce timelines and de-risk the development of genomic medicines.

3 investors

XGenomes develops DNA sequencing technology that combines novel biochemistry, hardware, and algorithms to sequence single molecules of DNA directly, without library preparation or a bioinformatics bottleneck. It aims to deliver complete, highly accurate genome sequencing at low consumable cost, offered first as a service and later via an instrument-and-consumables model.

3 investors

GAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.

2 investors

Kern Systems develops DNA-based data storage, using enzymatic DNA synthesis and custom digital codecs to encode information. It aims to build scalable information infrastructure stored in DNA as an alternative to current memory technologies.

2 investors

Spiral Genetics builds genomic data mining software for comparing large populations of whole human genomes using machine learning, aimed at enabling new diagnostics and druggable targets. Its customers include genetics testing companies, national governments, and pharmaceutical companies.

2 investors